CXCR4 and non-small cell lung carcinoma: Further, trial data combining plerixafor with ICIs shows evidence of CXCR4 inhibition improving T cell infiltration, leading to increased immune activation and thus, the immune response rate to treatment in NSCLC (Zhu et al., 2023).